Published in Curr Med Res Opin on March 16, 2012
Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control (2014) 0.76
Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol. Am Health Drug Benefits (2015) 0.75
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2011) 2.25
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ (2012) 2.05
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Subjective and objective measurement of human accommodative amplitude. J Cataract Refract Surg (2003) 1.85
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry (2003) 1.55
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother (2011) 1.51
Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation (2008) 1.39
Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin (2010) 1.31
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. J Biomol Screen (2012) 1.30
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring) (2007) 1.28
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke (2006) 1.24
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ (2011) 1.19
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics (2010) 1.10
Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol (2011) 1.10
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ (2011) 1.10
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes (2012) 1.09
Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health (2007) 1.08
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. J Manag Care Spec Pharm (2015) 1.06
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health (2012) 1.03
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther (2009) 1.02
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat (2013) 1.01
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther (2012) 1.01
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: a pilot study. Respirology (2010) 1.00
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol (2011) 0.99
Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin (2009) 0.98
Economic implications of treatment-resistant depression among employees. Pharmacoeconomics (2004) 0.95
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin (2014) 0.95
Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin (2009) 0.94
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig (2011) 0.92
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin (2011) 0.92
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
Intraoperative placement of the Copper T-380 intrauterine devices in women undergoing elective cesarean delivery: a pilot study. Contraception (2009) 0.89
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin (2013) 0.89
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med (2006) 0.88
Prevalence rate of myopia in schoolchildren in rural Mongolia. Optom Vis Sci (2006) 0.87
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf (2012) 0.86
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol (2012) 0.86
Serum urate and incidence of kidney disease among veterans with gout. J Rheumatol (2013) 0.86
Activated T cell trans-endothelial migration relies on myosin-IIA contractility for squeezing the cell nucleus through endothelial cell barriers. PLoS One (2013) 0.86
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin (2014) 0.86
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin (2014) 0.85
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2009) 0.85
Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol (2012) 0.85
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin (2010) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Employees with overactive bladder: work loss burden. J Occup Environ Med (2005) 0.84
Kinetic mechanism and rate-limiting steps of focal adhesion kinase-1. Biochemistry (2010) 0.84
Expression of BK-type calcium-activated potassium channel splice variants during chick cochlear development. J Comp Neurol (2010) 0.83
Development and validation of a claims-based prediction model for COPD severity. Respir Med (2013) 0.83
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Case report: ultrasound-guided continuous thoracic paravertebral block for outpatient acute pain management of multilevel unilateral rib fractures. Anesth Analg (2012) 0.83
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ (2013) 0.82
Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma (2007) 0.82
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin (2012) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin (2012) 0.82
Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One (2013) 0.81
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ (2011) 0.81
The role of health economics and outcomes research in health care reform in China. Pharmacoeconomics (2014) 0.81
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin (2015) 0.81
A multi-national report on methods for institutional credentialing for spine radiosurgery. Radiat Oncol (2013) 0.81
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. Curr Med Res Opin (2010) 0.81
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology (2010) 0.81
Burden of Illness of Diabetic Peripheral Neuropathic Pain: A Qualitative Study. Patient (2015) 0.81
Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin (2014) 0.81
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev (2013) 0.80
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ (2012) 0.80
Evaluating the validity and reliability of a modified survey to assess patient satisfaction with mail-order and community pharmacy settings. J Pharm Pract (2009) 0.80
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin (2015) 0.79
Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm (2012) 0.79
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin (2014) 0.79
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig (2011) 0.79
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. Curr Med Res Opin (2010) 0.79
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk. Am J Ther (2011) 0.79
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ (2012) 0.79
A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ (2013) 0.78
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin Breast Cancer (2012) 0.78
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol (2012) 0.78
Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. Bioorg Med Chem Lett (2010) 0.78
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer (2013) 0.78